INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Zikria Dean reported VBIO

Director, Interim CEO · Valion Bio, Inc. · Valion Bio, Inc. — Restricted Stock Units

Side
A
Value
—
Shares
50.0K
Price
—
Executed
Sep 22, 2026
Disclosed
Sep 24, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 22 executedSep 24, 2026 disclosed

VBIO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VBIO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    19
    WG
    Wolf Lisa GCOO & CFO
    VBIOValion Bio, Inc.
    Option exercise
    		M—
    4 sh
    		Sep 18, 2026Sep 24, 2026
    traded Sep 18, 2026
    		+6dSEC FORM 4

    Evidence

    23
    WG
    Wolf Lisa GCOO & CFO
    VBIOValion Bio, Inc.
    Option exercise
    		M—
    4 sh
    		Sep 18, 2026Sep 24, 2026
    traded Sep 18, 2026
    		+6dSEC FORM 4

    Evidence

    19
    WG
    Wolf Lisa GCOO & CFO
    VBIOValion Bio, Inc.
    Tax withholding
    		F$4.24
    2 sh
    		Sep 18, 2026Sep 24, 2026
    traded Sep 18, 2026
    		+6dSEC FORM 4

    Evidence

    47
    BS
    Bolton SheryleDirector
    TIVCValion Bio, Inc.
    Open-market purchase
    		BUY$10K
    10.0K sh
    		Apr 15, 2026Apr 20, 2026
    traded Apr 15, 2026
    		+5dSEC FORM 4

    Evidence

    9
    EJ
    Ernst JenniferDirector, Chief Executive Officer
    TIVCValion Bio, Inc.
    Option exercise
    		M—
    14.7K sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    9
    WG
    Wolf Lisa GChief Financial Officer
    TIVCValion Bio, Inc.
    Option exercise
    		M—
    736 sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    13
    EJ
    Ernst JenniferDirector, Chief Executive Officer
    TIVCValion Bio, Inc.
    Tax withholding
    		F$9,840
    5,262 sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    21
    WG
    Wolf Lisa GChief Financial Officer
    TIVCValion Bio, Inc.
    Tax withholding
    		F$565
    302 sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    9
    WG
    Wolf Lisa GChief Financial Officer
    TIVCValion Bio, Inc.
    Option exercise
    		M—
    736 sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    21
    EJ
    Ernst JenniferDirector, Chief Executive Officer
    TIVCValion Bio, Inc.
    Option exercise
    		M—
    14.7K sh
    		Dec 18, 2025Dec 22, 2025
    traded Dec 18, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001683168-26-007398
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 22, 2026
    Published
    Sep 24, 2026
    Ingested by INSIDER
    Nov 5, 02:15 UTC
    Last re-read
    Nov 5, 02:15 UTC

    Extracted facts

    Filer
    Zikria Dean
    Role
    Director, Interim CEO
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Valion Bio, Inc. — Restricted Stock Units
    Ticker
    VBIO
    Shares
    50.0K
    Price per share
    $0
    Execution date (reported)
    Sep 22, 2026
    Owned after transaction
    50.0K shares
    Days from execution to publication
    2

    What this establishes

    Zikria Dean filed this Form 4 reporting a grant or award of VBIO on Sep 22, 2026. It became public on Sep 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Interim CEO
    Zikria Deancik:0001877611
    Issuer
    Valion Bio, Inc.cik:0001787740

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.